The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | STRESS-LUNG-1: assessing the effect of stress on checkpoint inhibitor efficacy in NSCLC
Fang Wu, MD, Central South University, Hunan, China, discusses findings from the prospective, observational STRESS-LUNG-1 trial (NCT05477979), which assessed the effects of psychological stress on the efficacy of first-line immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer (NSCLC). Psychological stress was associated with lower survival, and clinicians should pay attention to the mental well-being of patients to improve their outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
